Price
Target price
€11.58
€11.58
-0.340%
-0.04
-0.340%
-
18:40 / Tradegate
WKN: 883790 / Symbol: FMOCF / Name: FCC / Stock / Professional & Commercial Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Fomento de Construcciones S.A. Stock
The price for the Fomento de Construcciones S.A. stock decreased slightly today. Compared to yesterday there is a change of -€0.040 (-0.340%).
Pros and Cons of Fomento de Construcciones S.A. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Fomento de Construcciones S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Fomento de Construcciones S.A. | -0.340% | -2.517% | 4.122% | -5.065% | 4.309% | 23.881% | 9.830% |
| Prosegur Compañía de Seguridad S.A | 0.780% | -1.346% | -4.824% | -4.291% | -1.346% | 47.753% | - |
| Donaldson Co. | 0.680% | 3.546% | - | - | - | - | - |
| Fti Consulting | 9.760% | -4.651% | -12.143% | -14.583% | -15.753% | -30.114% | 9.821% |
News
Anterix Eyes 900 MHz Monetization as FCC Order Opens Satellite Door
Key Points
- Interested in Anterix Inc.? Here are five stocks we like better.
- Anterix is pushing to monetize its 900 MHz spectrum by securing more utility contracts and developing new
INNOVATE Q1 Earnings Call Highlights
INNOVATE (NYSE:VATE) reported higher first-quarter revenue and a narrower loss as growth in its infrastructure business offset weaker results in its Life Sciences and Spectrum segments, management
NextNav Q1 Earnings Call Highlights
NextNav (NASDAQ:NN) executives said the company continues to advance its regulatory, testing and commercialization efforts tied to a